Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Adult men and non-pregnant, non-lactating women between 18 and 75 years of age. Sexually active females must be of either non-childbearing potential or willing to comply with the contraceptive requirements~* Body weight greater \>40 kg and \<120 kg with a body mass index (BMI) between 19-31 kg/m2~* Clinical history of rheumatoid arthritis as defined by ACR criteria~* Negative urine pregnancy test for women of child bearing age (except those with documented proof of hysterectomy or bilateral oophorectomy)~For populations B and C only~* Currently on a stable dosing regimen of methotrexate 7.5 to 25 mg once weekly, as their only DMARD (no changes in dosing regimen for 4 weeks prior to screening).~Exclusion criteria~* History of an acute illness within 2 weeks prior to the study~* History of drug abuse within 2 years~* Donation of blood in excess of 500 mL within 56 days prior to the first dose of study medication~For group A only~* Prior treatment with disease modifying anti-rheumatic agents or biologicals.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Naive patients (Type: None): 12 treatment naive patients who fulfil the American College of Rheumatology (ACR) criteria for RA with active disease defined by a Disease Activity Score (DAS)28 score of more than 3.2.
- Patients in remission (Type: None): 6 RA patients in remission on a stable dose of methotrexate with a DAS28 score lower than 2.6
- Patients still have active disease (Type: None): 12 patients who fulfill the ACR criteria for RA and are being treated with methotrexate but still have active disease, defined as a DAS28 score of more than 3.2

Based on this trial design, predict the completion outcome and termination type (if applicable).